Related Experiment Video
Updated: May 3, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.2K
Mortality risk with sulphonylureas compared to metformin.
1Cochrane Institute of Public Health, School of Medicine, Cardiff University, Cardiff, UK.
Diabetes, Obesity & Metabolism
|February 19, 2014
Summary
Metformin is the recommended first-line treatment for type 2 diabetes in the USA and UK. Sulfonylureas, while decreasing in use, may cause increased harm compared to metformin monotherapy.
Area of Science:
- Endocrinology
- Pharmacology
- Clinical Medicine
Background:
- Current clinical guidelines in the USA and UK advocate metformin monotherapy for type 2 diabetes management.
- The utilization of sulfonylureas as a first-line treatment is declining.
- This shift necessitates a review of the comparative risks and benefits of these monotherapies.
Purpose of the Study:
- To critically evaluate the risks and benefits of sulfonylurea monotherapy versus metformin monotherapy.
- To examine the evidence regarding the comparative safety profiles of sulfonylureas and metformin in type 2 diabetes.
Main Methods:
- This is a commentary, not a primary research study.
- It involves a critical review and synthesis of existing clinical guidelines and scientific literature.
- Evidence from comparative studies on glucose-lowering treatments is discussed.
Main Results:
- Metformin is the preferred first-line agent according to current guidelines.
- Sulfonylureas are associated with a decreasing proportion of treatment.
- Evidence suggests sulfonylureas may lead to increased harm compared to metformin.
Conclusions:
- Metformin monotherapy remains the recommended first-line treatment for type 2 diabetes.
- The use of sulfonylureas should be carefully considered due to potential increased harm.
- Further evidence supports the established guideline recommendations.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:26Hypoglycemia
30
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
01:30Drug toxicity: Drug–Drug Interaction
423
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
423
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953